TASS program (Anamar Medical/Acure Pharma)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTASS program (Anamar Medical/Acure Pharma)
Drug Alias NameAM-260 TASSAM-260
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2 (5-HT2) receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 2 (5-HT2) receptor
Therapy Area/IndicationsPainDermatitisOsteoarthritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMar-Med
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMar-MedAcure Pharma AB
Active IndicationsN/A
Inactive IndicationsPainDermatitisOsteoarthritis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A